The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for ruxolitinib (as phosphate) (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
ruxolitinib (as phosphate)
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablets
Indication
Jakavi is indicated for the treatment of patients with Graft versus Host Disease (GvHD).
Therapeutic area
Immunology